Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics
Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics
复制标题
DOI：
10.4155/tde.12.41
复制
发表时间：
2012-05-01
影响因子：
4.2
通讯作者：
Lacko, Andras G.
中科院分区：
文献类型：
--
作者：
Sabnis, Nirupama;Lacko, Andras G.
血浆脂蛋白是哺乳动物循环中脂质和其他疏水分子的转运蛋白。脂蛋白由于其体积小、在循环中的停留时间长和高药物有效载荷，也具有作为药物递送载体的强大潜力。因此，脂蛋白和合成/重构脂蛋白制剂已被评估，对临床应用，特别是癌症诊断/成像和化疗越来越感兴趣。在这篇综述中，过去和目前的研究脂蛋白和类似的替代药物载体进行了讨论，关于其适合作为代理商提供药物，主要是癌细胞和肿瘤。基于脂蛋白的递送策略还可以提供一种新的平台，用于改善先前被认为不合适或由于溶解性差而仅具有有限应用的药物的治疗功效。通过脂蛋白型载体的药物递送过程的另一个且可能是最重要的方面是受体介导的从脂蛋白复合物摄取有效载荷。因此，在治疗前监测特异性受体的表达可以有效地选择最佳反应的患者，从而产生成功的个性化治疗方案。
Plasma lipoproteins are transporters of lipids and other hydrophobic molecules in the mammalian circulation. Lipoproteins also have a strong potential to serve as drug-delivery vehicles due to their small size, long residence time in the circulation and high-drug payload. Consequently, lipoproteins and synthetic/reconstituted lipoprotein preparations have been evaluated with increasing interest towards clinical applications, particularly for cancer diagnostics/imaging and chemotherapy. In this review, past and current studies on lipoproteins and similar alternative drug carriers are discussed regarding their suitability as agents to deliver drugs, primarily to cancer cells and tumors. A lipoprotein-based delivery strategy may also provide a novel platform for improving the therapeutic efficacy of drugs that have previously been judged unsuitable or had only limited application due to poor solubility. An additional, and perhaps the most important aspect of the drug-delivery process via lipoprotein-type carriers, is the receptor-mediated uptake of the payload from the lipoprotein complex. Monitoring the expression of specific receptors prior to treatment could, thus, give rise to efficient selection of optimally responsive patients, resulting in a successful personalized therapy regimen.